Takeda files for azilsartan medoxomil in the US
This article was originally published in Scrip
Takeda has filed a US NDA for its antihypertensive drug azilsartan medoxomil (TAK-491).
You may also be interested in...
Join Scrip and the Pink Sheet’s Asia content team for a wide-ranging look at the ongoing multiple impacts of the pandemic on the pharma industry.
Japanese firm says it will end SHP647 development after trying unsuccessfully to find takers for GI drug similar to its blockbuster Entyvio, first flagged by European authorities over competition worries.